Bars are graphed using the scale on the y-axis to the left; lines are graphed using the scale on the y-axis to the right. ANDA indicates abbreviated new drug applications.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jiao K, Gupta R, Fox E, Kesselheim A, Ross JS. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration. JAMA Netw Open. 2019;2(10):e1913029. doi:https://doi.org/10.1001/jamanetworkopen.2019.13029
Generic drugs have an essential role in the US health care system, providing less costly and equally safe and effective alternatives to brand-name drugs. Insufficient generic competition and shortages of older, off-patent drugs have disrupted care for patients and limited potential cost savings.1,2 In response, the US Food and Drug Administration (FDA) has taken a series of actions since 2017, including releasing the Drug Competition Action Plan3 and implementing certain aspects of the Generic Drug User Fee Amendments included in the FDA Reauthorization Act, to promote competition among drugs no longer protected by market exclusivity and expedite application review of generic drugs. The objective of this study was to characterize recent generic drug approvals, particularly for drugs that faced limited competition or had previously been in shortage.
For this cross-sectional study, we used the Drugs@FDA database to identify all abbreviated new drug applications (ANDAs) approved by FDA from July 1, 2016, to December 31, 2018. We excluded tentative approvals, biologic treatments, over-the-counter products, and discontinued ANDAs. For each ANDA, we determined competition per FDA policy,3 categorized as the presence of 2 or fewer vs 3 or more existing manufacturers of the generic drug at the time of approval. Prior drug shortage was defined as any drug shortage lasting 1 month or longer for the same active ingredient and dosage from within 5 years prior to approval, determined using the University of Utah’s Drug Information Service drug shortage database.1 For each ANDA, we also characterized the corresponding brand-name drug’s initial approval year, priority review status, Orphan Drug Act designation, World Health Organization essential medicine status, therapeutic area based on World Health Organization Anatomical Therapeutic Chemical code classification, and drug complexity, the latter using previously described methods.2 We used descriptive statistics to characterize trends in recent generic drug approvals. We plotted quarterly trends from July 2016 to December 2018, including the proportion of ANDA approvals in each quarter (Q) that were drugs with limited competition and with prior drug shortage. We used SAS statistical software version 9.4 (SAS Institute) and Excel 2019 (Microsoft Corp) to conduct descriptive analyses without statistical testing. Because this study did not use patient data, it was exempt from review by the Yale Human Investiagtion Committee. Data analyses were conducted between March and August 2019. This study was reported using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
There were 1832 ANDAs approved by the FDA from July 2016 to December 2018 (Figure), covering 533 different active ingredients. There were 133 ANDA approvals in Q3 2016, which initially increased over time before decreasing to 102 ANDA approvals in Q1 2018, but increased again to 262 ANDA approvals in Q4 2018. The corresponding brand-name drugs for these generic drugs were most commonly approved from 1995 to 2004 (761 drugs [41.5%]) and used to treat neurologic (426 drugs [23.3%]), cardiovascular (256 drugs [14.0%]), or infectious (229 drugs [12.5%]) diseases; 456 drugs (24.9%) received priority review, 244 drugs (13.3%) were designated as orphan drugs, 364 drugs (19.9%) were listed as World Health Organization essential medicines, and 351 drugs (19.2%) were determined to be complex drugs (Table).
Among 1832 ANDA approvals, 374 (20.4%) were in limited competition at the time of approval, ranging from 27 drugs (14.2%) in Q3 2017 to 39 drugs (29.3%) in Q3 2016. In addition, 717 drugs (39.1%) had experienced a shortage in the previous 5 years, ranging from 45 drugs (28.1%) in Q4 2016 to 107 drugs (46.1%) in Q4 2017.
From July 2016 to December 2018, the total number of generic drug applications approved by the FDA increased slightly, but the proportion of approvals for drugs that faced limited competition or had previously been in shortage remained steady. Our study has limitations, as we only characterized FDA approvals, not whether companies brought their approved drug to market after approval.4 Also, while we followed the FDA’s policy defining limited generic competition, prior studies have used a definition of 3 or fewer existing manufacturers.5,6 Although our results suggest that there have not yet been noticeable effects of the FDA’s initiatives to expand approvals for generic drugs at risk for price spikes and shortages, ANDAs take time for the manufacturer to prepare and then another 6 to 12 months for regulatory review. Nevertheless, continued attention is needed to foster approval of generic drugs with limited competition and prior shortage.
Accepted for Publication: August 19, 2019.
Published: October 11, 2019. doi:10.1001/jamanetworkopen.2019.13029
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Jiao K et al. JAMA Network Open.
Corresponding Author: Joseph S. Ross, MD, MHS, Section of General Internal Medicine, Department of Medicine, Yale University School of Medicine, PO Box 208093, New Haven, CT 06520 (firstname.lastname@example.org).
Author Contributions: Mr Jiao and Dr Ross had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Jiao, Gupta, Kesselheim, Ross.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Jiao.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Jiao.
Obtained funding: Kesselheim.
Supervision: Kesselheim, Ross.
Conflict of Interest Disclosures: Dr Fox reported serving on the advisory board of the Joint Commission of Pharmacy Practitioners and receiving partial travel support from the Association of American Medical Colleges, Mayo Clinic, European Cooperation in Science and Technology, American Society of Health-System Pharmacists, International Society for Pharmacoepidemiology, University of Illinois, American College of Clinical Pharmacy, University of Iowa, American Society of Anesthesiologists, and National Academies of Sciences, Engineering, and Medicine; partial travel support to provide continuing education from Anesthesia Patient Safety Foundation, Massachusetts Society of Health System Pharmacists, Idaho Society of Health System Pharmacists, Mature Health Communications, Infusion Nurses Society, Premier Oncology Hematology Management Society, Oklahoma Society of Health System Pharmacists, and Cleveland Clinic Abu Dhabi outside the submitted work; and that the University of Utah has a contract to provide drug shortage information to Vizient. Dr Kesselheim reported receiving grants from Arnold Ventures and the Harvard-MIT Center for Regulatory Science during the conduct of the study. Dr Ross reported receiving grants from the Food and Drug Administration, Centers for Medicare & Medicaid Services, Johnson and Johnson, Medtronic; Blue Cross Blue Shield Association, Agency for Healthcare Research and Quality, National Heart, Lung, and Blood Institute, National Institutes of Health, and Laura and John Arnold Foundation outside the submitted work. No other disclosures were reported.
Create a personal account or sign in to: